Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Formulary Controversy | Statement: [Unigenitus Dei Filius, relatedTo, Formulary Controversy]

Target entity: Formulary Controversy
Context triple: [Unigenitus Dei Filius, relatedTo, Formulary Controversy]

• A. 340B Drug Pricing Program
  The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
• B. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• C. Prescription Drug Marketing Act
  The Prescription Drug Marketing Act is a U.S. federal law that regulates the distribution and marketing of prescription drugs to ensure their safety, effectiveness, and integrity within the pharmaceutical supply chain.
• D. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• E. Medicaid Drug Rebate Program
  The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Formulary Controversy
Target entity description: The Formulary Controversy was a 17th-century theological and political dispute within the French Catholic Church over the required acceptance of an anti-Jansenist doctrinal formula, pitting Jansenist sympathizers against royal and papal authorities.

• A. 340B Drug Pricing Program
  The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
• B. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• C. Prescription Drug Marketing Act
  The Prescription Drug Marketing Act is a U.S. federal law that regulates the distribution and marketing of prescription drugs to ensure their safety, effectiveness, and integrity within the pharmaceutical supply chain.
• D. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• E. Medicaid Drug Rebate Program
  The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
• F. None of above. chosen